

# RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,  
UP – 201304, Website- www.raymedlab.com

E-mail- [raymedlabs@rediffmail.com](mailto:raymedlabs@rediffmail.com), Phone no. - 0120-2426900, 9412700300

---

Date: 14.02.2020

To,  
Head Listing Compliance,  
**BSE Limited**,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

**Security Code: 531207**

**Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today i.e. **Friday, 14<sup>th</sup> February, 2020** (commenced at 04:00 P.M and concluded at 05:50 P.M.) has inter alia approved and passed the following resolutions:

1. **Unaudited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and nine months ended on December 31, 2019.
2. Taking note of the **Limited Review Report** as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter and nine months ended on December 31, 2019.
3. Taking note of **Statement of Investor Complaints/Grievances** under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended on December 31, 2019

# RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,  
UP – 201304, **Website-** www.raymedlab.com

**E-mail-** [raymedlabs@rediffmail.com](mailto:raymedlabs@rediffmail.com), **Phone no.** - 0120-2426900, 9412700300

---

Kindly take the above information on your records.

Thanking you,


Yours Sincerely,

**For Raymed Labs Limited**

AJAI  
GOYAL

Digitally signed  
by AJAI GOYAL  
Date: 2020.02.14  
17:59:30 +05'30'

**Ajai Goyal**  
**Whole time Director**  
**DIN: 02636418**



# A. Kay Mehra & Co.

**CHARTERED ACCOUNTANTS**

2470 (Basement), Hudson Line, GTB Nagar, Delhi-110009

Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

**Limited Review Report for the quarter and period ended 31st December, 2019 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors  
**Raymed Labs Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Raymed Labs Limited** ("The Company") for the quarter ended 31<sup>st</sup> December, 2019, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Indian Accounting standard Specified under section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. Kay Mehra & Co.

Chartered Accountants

F.R.N.:050004C



CA Deepak Suneja

Partner

Membership No. 501957

Place: New Delhi

Date : 14.02.2020

UDIN - 20501957AAADCC1770

## Raymed Labs Limited

Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN:  
L241111UP1992PLC014240

### Statement of Standalone Un-Audited Financial Results for the Quarter Ended on December 31, 2019

		Quarter Ended			Nine Months Ended		Year Ended
		Amounts in Lakhs					
	Particulars	Quarter Ended	Preceding 3	Correspondin	Year to Date	Year to Date	31-03-2019
		31-12-2019	Months	g 3 Months	Figures for	Figures for	
		Unaudited	Ended	Ended in the	Current Year	Previous Year	
		31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	Audited
I	<b>Revenue from Operations</b>						
	(a) Net Sales / Income from Operations (Net of	-	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	-	-
II	<b>Other Income</b>	0.33	0.33	0.33	0.99	0.93	1.26
III	<b>Total Revenue (I+II)</b>	<b>0.33</b>	<b>0.33</b>	<b>0.33</b>	<b>0.99</b>	<b>0.93</b>	<b>1.26</b>
IV	<b>Expenses</b>						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, Work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee Benefits Expenses	0.23	0.55	0.30	1.38	0.75	1.35
	(e) Finance Costs	-	-	-	-	-	-
	(f) Depreciation and amortisation expense	0.15	0.15	0.16	0.45	0.48	0.64
	(g) Other expenses	0.22	0.37	0.46	1.84	1.16	1.68
	<b>Total Expenses</b>	<b>0.60</b>	<b>1.07</b>	<b>0.92</b>	<b>3.66</b>	<b>2.39</b>	<b>3.66</b>
V	<b>Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)</b>	<b>(0.27)</b>	<b>(0.74)</b>	<b>(0.59)</b>	<b>(2.67)</b>	<b>(1.46)</b>	<b>(2.40)</b>
VI	<b>Exceptional Items</b>	2.36	-	-	2.36	2.95	2.95
VII	<b>Profit/(Loss) before extraordinary items and tax</b>	<b>(2.63)</b>	<b>(0.74)</b>	<b>(0.59)</b>	<b>(5.03)</b>	<b>(4.41)</b>	<b>(5.35)</b>
VIII	<b>Extraordinary items</b>	-	-	-	-	-	-
IX	<b>Profit/(Loss) before tax (VII-VIII)</b>	<b>(2.63)</b>	<b>(0.74)</b>	<b>(0.59)</b>	<b>(5.03)</b>	<b>(4.41)</b>	<b>(5.35)</b>
X	<b>Tax Expense</b>	-	-	-	-	-	-
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-	-
XI	<b>Net Profit/(Loss) for the period from continuing operations (IX-X)</b>	<b>(2.63)</b>	<b>(0.74)</b>	<b>(0.59)</b>	<b>(5.03)</b>	<b>(4.41)</b>	<b>(5.35)</b>
XII	<b>Profit/(Loss) from discontinuing operations</b>	-	-	-	-	-	-
XIII	<b>Tax expense of discontinuing operations</b>	-	-	-	-	-	-
XIV	<b>Profit/(Loss) from Discontinuing operations</b>	-	-	-	-	-	-
XV	<b>Profit/(Loss) for period before Minority interest</b>	-	-	-	-	-	-
	Share of profit/Loss of Associates	-	-	-	-	-	-
	Profit/(Loss) of Minority interest	-	-	-	-	-	-
XVI	<b>Profit/(Loss) for the period (XI+XIV)</b>	<b>(2.63)</b>	<b>(0.74)</b>	<b>(0.59)</b>	<b>(5.03)</b>	<b>(4.41)</b>	<b>(5.35)</b>
XVII	<b>Paid-up share capital (Face Value of the share</b>	427.35	427.35	427.35	427.35	427.35	427.35
XVIII	<b>Reserve excluding revaluation reserve as per</b>	-	-	-	-	-	-
XIX	<b>Earning Per Equity Share</b>						
	(a) Basic	-0.061	-0.017	-0.014	-0.118	-0.103	-0.125
	(b) Diluted	-0.061	-0.017	-0.014	-0.118	-0.103	-0.125

**Notes:**

- (1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 14th February, 2020. The Statutory Auditors have carried out their limited review of the above results.
- (2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- (3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- (4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year
- (5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

For Raymed Labs Limited

**AJAI** Digitally signed  
by AJAI GOYAL  
**GOYAL**  
Date:  
2020.02.14  
17:58:58 +05'30'

Ajai Goyal  
Wholetime Director  
DIN: 02636418

Date: 14.02.2020  
Place: Noida

# RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,  
UP – 201304, Website- www.raymedlab.com

E-mail- [raymedlabs@rediffmail.com](mailto:raymedlabs@rediffmail.com), Phone no. - 0120-2426900, 9412700300

---

Date: 14.02.2020

To,  
Head Listing Compliance,  
**BSE Limited**,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

**Security Code: 531207**

**Subject: Non Applicability of Compliance with Statement of Deviation(s) or Variation(s) as per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the quarter ended December 31, 2019**

Dear Sir/Madam,

With reference to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the disclosure of Statement of Deviation(s) or Variation(s) as per the said regulation is not applicable to the Company.

Kindly take the same in your records.

Thanking you,

Yours Sincerely,  
**For Raymed Labs Limited**

**AJAI**  
**GOYAL**  
Digitally signed  
by AJAI GOYAL  
Date:  
2020.02.14  
18:00:01 +05'30'

**Ajai Goyal**  
**Whole time Director**  
**DIN: 02636418**